Mira Pharmaceuticals (MIRA) Cash from Operations (2022 - 2025)
Mira Pharmaceuticals' (MIRA) quarterly Cash from Operations came in at 1173368.0 in Q4 2025, up 34.99% year-on-year from 869196.62 in Q4 2024, and down 4.15% quarter-over-quarter from 1126632.0 in Q3 2025.
Mira Pharmaceuticals (MIRA) Cash from Operations (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals has disclosed Cash from Operations across 4 years of filings, most recently posting 1173368.0 for Q4 2025.
- Cash from Operations for Q4 2025 came in at 1173368.0, up 34.99% year-over-year; the trailing twelve-month figure through Dec 2025 was 4700000.0 (up 15.48% YoY), and the FY2025 annual result was 4700000.0, up 15.48% from the prior year.
- Cash from Operations came in at 1173368.0 for Q4 2025 at Mira Pharmaceuticals, down from 1126632.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 660813.0 in Q2 2023 to a low of 1842111.0 in Q3 2024.
- The 4-year median for Cash from Operations is 1100969.0 (2023), against an average of 1220245.36.
- Across the five-year window, Cash from Operations plunged 74.4% in 2024 and jumped 38.84% in 2025, its largest moves.
- Mira Pharmaceuticals' Cash from Operations stood at 975436.0 in 2022, then retreated by 6.11% to 1035015.0 in 2023, then slumped by 74.4% to 1805030.0 in 2024, then soared by 34.99% to 1173368.0 in 2025.
- The last three Cash from Operations figures came in at 1173368.0 (Q4 2025), 1126632.0 (Q3 2025), and 800000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.82 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Mira Pharmaceuticals | 22.73 Mn | 11.70 Mn | - | -1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.17 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -800,000.00 |
| Jun 30, 2025 | -800,000.00 |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.81 Mn |
| Dec 31, 2024 | -1.81 Mn |
| Sep 30, 2024 | -1.84 Mn |
| Sep 30, 2024 | -1.84 Mn |
| Jun 30, 2024 | -863,929.00 |
| Jun 30, 2024 | -863,929.00 |
| Mar 31, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Sep 30, 2023 | -1.76 Mn |